Novus, Medical M&A Company Enters Medicinal Cannabis Industry


Share Tweet

Novus, Medical M&A Company Enters Medicinal Cannabis Industry

MIAMI, FL / ACCESSWIRE / Mar 4, 2014 / Novus Acquisition & Development Corp. (OTC Pink: NDEV) has formed a subsidiary called Novus MMJ, Inc. known for its expertise in the medical marijuana field (“MMJ or Cannabis”) to add to our health portfolio.

NDEV was approached by Healthcare executives to gain access to an industry with an over a $6 billion market cap over the past 2 months. The investment community should know that NDEV business model is seizing opportunities in the regulated MMJ industry. The business model approach is primary development in Healthcare, Pharma, Physicians Education, Compliance, Security/Law Enforcement and the Business Development aspects. We will provide turnkey operations through methods of acquiring real property, equipment, Healthcare market positioning, Research and Development in Pharma (cannabis compounding) and Intellectual Property then lease back to the cultivators, dispensaries along with other ancillary business products and services to assist MMJ licensors in their business needs.

NDEV has initiated the following goals to be better positioned to address the needs of the Medicinal Cannabis industry:

- Create a board of advisors

- Finalize its Audit to become a reporting company for full transparency and move to the bulletin board

- Procure and/or create federally recognized software to track seed to sale and more

- Sign agreements with DNA Testing and Cannabis Compound laboratories for product development

- Purchase land and develop growing facilities for leasing purposes and potential R&D

To learn more details you can visit:


About Novus
Novus is comprised of seasoned Wall Street veterans that have focused its business model in the cannabis industry. Management and its proposed future Board of Directors areas of expertise will diversify in Healthcare, Physicians Education, Pharma R&D, Compliance and Business Development. NDEV will work as an outside developer and since it not Federally approved it will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.

For investor Relations contact:
Bridgewater Communications Group
Main Tel: (855) 4-BCG-INFO / (855) 422-4463
Email: [email protected]

Contact Novus
Gary F. Labrozzi, CEO


Source: Novus Acquisition & Development Corp.